EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE)

Jacquelyn Crawford iD, Austin Roe, Jessica Brumit iD, Vera Wilson, Jen Tharp

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241271264 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Jacquelyn Crawford und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Johnson City Medical Center, Johnson City, TN, USA. Hauptthemen laut MEDLINE: Tenecteplase, Pulmonary Embolism, Fibrinolytic Agents, Tissue Plasminogen Activator. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thrombolysis is recommended in the setting of massive pulmonary embolism (PE) for reperfusion of vessels but carries a serious concern for increased bleed risk. In October 2022, our institution adopted tenecteplase as the formulary thrombolytic. Previous literature is unclear regarding the bleed risk of tenecteplase in massive PE, and no study has yet compared safety outcomes with the current standard of care, alteplase.

Objective

The objective of this study was to compare the incidence of bleeding with tenecteplase versus alteplase in massive PE patients.

Methods

This was a retrospective, observational cohort study that included adults who received tenecteplase or alteplase for massive PE. The primary outcome was major bleeding as defined by the International Society on Thrombosis and Hemostasis (ISTH). Secondary outcomes included incidence of symptomatic intracranial hemorrhage (ICH), in-hospital mortality, administration of reversal agents, and length of stay.

Results

A total of 44 patients met inclusion criteria with 20 patients in the alteplase cohort and 24 in the tenecteplase cohort. Seventeen percent of tenecteplase patients compared with 5% of alteplase patients experienced bleeding. The mortality rate was 83% vs 75%, respectively. In addition, 1 patient in the tenecteplase cohort experienced a symptomatic ICH and 2 patients required initiation of massive transfusion protocol. Conclusion and Relevance: Although this study was limited in sample size, these results suggest that there may be reason for concern of higher bleeding rates in patients treated with tenecteplase in the setting of massive PE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenecteplasePulmonary EmbolismFibrinolytic AgentsTissue Plasminogen ActivatorHemorrhageHumansRetrospective StudiesMaleFemaleMiddle AgedAgedHospital MortalityTreatment OutcomeCohort StudiesIntracranial Hemorrhages

Stichwörter der Autor:innen

bleedingclinical pharmacologyintracranial hemorrhagemedication safetypulmonary embolismthrombolysisthrombolytics

Substanzen

TenecteplaseFibrinolytic AgentsTissue Plasminogen Activator

Autor:innen und Institutionen

  • Department of Pharmacy, Johnson City Medical Center, Johnson City, TN, USA.

ORCID-Profile: Jacquelyn Crawford, Jessica Brumit

Zitieren

APA

Crawford, J., Roe, A., Brumit, J., Wilson, V., & Tharp, J. (2025). Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE). Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241271264

Vancouver

Crawford J, Roe A, Brumit J, Wilson V, Tharp J. Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE). Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241271264

BibTeX
@article{Crawford2025,
  author = {Crawford, Jacquelyn and Roe, Austin and Brumit, Jessica and Wilson, Vera and Tharp, Jen},
  title = {Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE)},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241271264}
}
Kostenlos starten →